bluejaydx.com (BJDX) - Cash per Share

Bluejay Diagnostics (BJDX) develops rapid sepsis diagnostic systems, generating steady revenue from the sale of consumables. Quarterly cash per share clearly demonstrates liquidity trends, while 6.56 reflects the most recent value of this metric. The business remains independent of economic cycles due to insurance reimbursements. However, high engineering costs constrain operational efficiency until a multi-fold increase in orders is achieved.
Comprehensive metric breakdowns and analytics for Bluejay Diagnostics Inc (BJDX)

Liquidity is a critical survival factor for the tech startup Bluejay Diagnostics (BJDX). This chart of cash per share illustrates the ratio of cash to the number of securities, reaching a value of 6.56. This indicator determines the financial cushion available for scaling the production of Symphony AI analyzers. Steady growth in this metric confirms balance sheet resilience, while a sharp decline signals the risk of a secondary offering. It is essential for investors to maintain a balance between security and capital efficiency.